FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT AKTIVA DI-N-PROPYLMETYLAMINDERIVAT

Methylamine derivs. of formula (I) and their addition salts are novel cpds. (where R1, R3 = H or a 1-6C linear or branched alkyl, alkenyl or alkynyl radical; R2 = 2-7C, linear or branched alkyl, alkenyl or alkynyl with the condition that when R2=alkenyl of formula -CH=CH-R6 or alkynyl of formula -C=C=R6 (where R6 = H or 1-5C linear or branched alkyl) then R1 and R3 = H or alkyl; r4 =H, 1-5C linear or branched alkyl, alkenyl or alkynyl or 2-5C omega-hydroxyalkyl; R5 = 1-5C, linear or branched alkyl, alkenyl or alkynyl or 2-5C omega-hydroxyalkyl or R4 and R5 together = 2-6C alkylene, 1-5C alkylidene or -CH2-CH2-O-CH2-CH2-; R1, R2 and R3 are such that the trisubstdmethyl radical contains =13C atoms). Used for treatment of Parkinsons disease and correction of extrapyramidal troubles caused by neuroleptics. Pharmacological tests show their central noradrenergic and central dopaminergic activity and they have less side-effects than the cpds. of the parent patent and first addition. They may be administered orally (unit doses 5-50 mg pref. 5-20 mg), rectally (5-100 mg) or parenterally (1-20 mg).